Enveric Biosciences, Inc. — Earnings

Most recent reported period: FY2025 (Q3) (filed for period ending 2025-09-30) · sourced from SEC EDGAR

Next earnings (estimated): Tue, December 30, 2025 122 days overdue (likely already filed but EDGAR cache cold). Anchored to latest quarter-end + 91 days. Analyst-confirmed dates land in a follow-up wave.
YoY = vs same quarter prior year (seasonality-adjusted)

Recent earnings · last 8 quarters

Quarter endRevenueYoYNet IncomeYoYOp. Margin
2025-12-31
2025-09-30$274↑+226.3%$-2M↑+10.1%-683920.8%
2025-06-30$-132↓-277.1%$-3M↓-34.0%1908370.5%
2025-03-31$2↓-99.7%$-2M↑+11.1%-109376650.0%
2024-12-31
2024-09-30$-217↓-109.7%$-2M↑+26.2%959996.3%
2024-06-30$-35↓-103.8%$-2M↑+70.4%5422660.0%
2024-03-31$696↑+6427.3%$-2M↑+47.5%-355936.4%

Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.

Last earnings · FY2025 (Q3)

Revenue
$274

Earnings surprise · last 8 quarters

YoY % change · proxy for analyst surprise until estimates land

EPS history · last 10 fiscal years

diluted, GAAP, annual

Note: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.

Margin trends · 63 quarters

margin trajectory tells the operating-leverage story
Gross Margin↑+1.5pts
22.3%
Operating Margin↓-1643917.1pts
-683920.8%
Net Margin↓-1644204.2pts
-683820.8%

Go deeper